Analysis of very important pharmacogene variants in the Tibetan population from China
- 20 April 2020
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 48 (5), 668-678
- https://doi.org/10.1111/1440-1681.13327
Abstract
Personalized medicine, the best treatment suited for an individual, is a hot field of clinical research in the world. Many recent studies have shown that genetic variations had a great influence on the treatment. The study aimed to identify the distribution differences of very important pharmacogene (VIP) variants between the Tibetan population and the 26 populations. Based on the PharmGKB database, we successfully genotyped 50 VIP variants located in 27 genes in the Tibetan population. We also compared the genotype frequencies of VIP variants between Tibetan and the 26 populations from the 1000 Genomes project. Without adjustment, the Chi‐square test showed that the only significant variant between Tibetans and every other group was rs1801159 in dihydropyrimidine dehydrogenase (DPYD), followed by rs1800566 in NAD(P)H quinone dehydrogenase 1 (NQO1) and rs1051296 in solute carrier family 19 member 1 (SLC19A1). After Bonferroni’s multiple adjustments, the genotype frequencies distribution of DPYD rs1801159 was found to be different in Tibetans compared to 26 groups, apart from ACB and ASW. Moreover, genetic structure/F‐statistics (Fst) analysis and the phylogenetic tree illustrated that Tibetans had a closer affinity with CDX, CHB, CHS, JPT and KHV. Our data will complement pharmacogenomics information of the Tibetan population and provide theoretical support for the realization of individualized medical treatment for Tibetans in the future.Keywords
This publication has 19 references indexed in Scilit:
- DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)JNCI Journal of the National Cancer Institute, 2014
- Pharmacogenomics: accessing important alleles by imputation from commercial genome-wide SNP arraysEvolution, 2014
- Potential of Dihydropyrimidine Dehydrogenase Genotypes in Personalizing 5-Fluorouracil Therapy Among Colorectal Cancer PatientsTherapeutic Drug Monitoring, 2013
- Pharmacogenomics and Individualized Medicine: Translating Science Into PracticeClinical Pharmacology & Therapeutics, 2012
- A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapyClinica Chimica Acta; International Journal of Clinical Chemistry, 2012
- Differences in mtDNA whole sequence between Tibetan and Han populations suggesting adaptive selection to high altitudeGene, 2012
- Common variants near TERC are associated with mean telomere lengthNature Genetics, 2010
- Basics of Personalized MedicinePublished by Springer Science and Business Media LLC ,2009
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsThe New England Journal of Medicine, 2003
- Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomicsPharmacogenomics, 2002